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Rationale: Recent studies described association between chronic obstructive pulmonary disease 
(COPD) and increased risk of cardiovascular diseases (CVD). In their analysis none of these 
studies accounted for sociodemographic factors, health behaviors, and patient comorbidities 
simultaneously.
Objective: To study whether COPD diagnosis is an independent risk factor for CVD.
Methods: Subjects aged 40 years and older (N = 18,342) from the sample adult file of the 2002 
National Health Interview Survey (NHIS) were included in the analysis. Chi-squared tests and 
odds ratios (OR) were utilized to compare the data. Multiple logistic regression was employed 
to analyze the association between COPD and CVD with simultaneous control for sociodemo-
graphic factors (age, gender, race, marital status, education, income), health behaviors (tobacco 
use, alcohol consumption, physical activity), and patient comorbidities (diabetes, hypertension, 
high cholesterol, and obesity). The analysis employed NHIS sampling weights to generate data 
representative of the entire US population.
Results: The COPD population had increased prevalence of CVD (56.5% vs 25.6%; P  0.0001). 
Adjusted logistic regression showed that COPD patients (N = 958) were at higher risk of having 
coronary heart disease (OR = 2.0, 95% CI: 1.5–2.5), angina (OR = 2.1, 95% CI: 1.6–2.7), 
myocardial infarction (OR = 2.2, 95% CI: 1.7–2.8), stroke (OR = 1.5, 95% CI: 1.1–2.1), 
congestive heart failure (OR = 3.9, 95% CI: 2.8–5.5), poor circulation in lower extremities 
(OR = 2.5, 95% CI: 2.0–3.0), and arrhythmia (OR = 2.4, 95% CI: 2.0–2.8). Overall, the presence 
of COPD increased the odds of having CVD by a factor of 2.7 (95% CI: 2.3–3.2).
Conclusions: These findings support the conclusion that COPD is an independent risk factor 
for CVD.
Keywords: chronic obstructive pulmonary disease, cardiovascular disease, risk factors, 
population-based analysis, case-control study
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
of adults in United States and it is projected to be the third leading cause of death 
by 2020.1 Nonrespiratory diseases account for more than 50% of deaths in COPD 
patients.2 A number of previous studies demonstrated an association between COPD 
and cardiovascular disease.3–11 In fact, the presence of COPD may be an independent 
risk factor for the development of cardiovascular disease (CVD) above that associated 
with the most widespread factor these diseases have in common, namely smoking.5–9 
Further, the Lung Health Study showed that age, smoking, male gender, married state, 
higher diastolic blood pressure, and poor pulmonary function were the strongest International Journal of COPD 2009:4 338
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cardiovascular risk factors in COPD, while high baseline 
forced expiratory volume in one second (FEV1), alcohol use, 
smoking cessation, and education were protective factors.12
Data consistent with the notion that COPD could be an 
independent risk for CVD come from the population-based 
studies13,14 that showed that the lower the FEV1, the higher 
the risk of CVD. However, many conditions, including 
heart failure and other lung diseases, can result in a reduced 
FEV1. Thus these studies are not specific for COPD. In a 
longitudinal health cohort study, Curkendall and colleagues 
showed that the diagnosis “COPD” increased the risk for 
hospitalization and deaths due to CVD.6 However, in this 
study, no simultaneous adjustment for sociodemographic 
and lifestyle risk factors for CVD, including physical activity, 
alcohol consumption, and smoking, was performed. Thus, 
while there are some indications that COPD may be a risk 
factor per se, to date only suggestive data have been presented. 
Further there are no US population based studies addressing 
the potential that COPD is a risk factor for CVD.
The notion that COPD itself is an independent risk for 
CVD has potentially important implications. As a systemic 
inflammatory disease, COPD may accelerate the develop-
ment of CVD above and beyond that due to smoking alone.11 
Indeed, if the risk were great enough, therapy directed at 
reducing cardiovascular risk might be indicated in COPD 
patients even without evidence of concomitant CVD, or the 
presence of other known risk factors aside from smoking.
This study used data from the National Health Interview 
Survey (NHIS), a representative sample of the civilian, 
noninstitutionalized, adult US population to investigate 
the association between COPD and CVD. Our aims were: 
1) To measure prevalence of CVDs in COPD patients; 2) to 
determine if the diagnosis of COPD is an independent risk 
factor for CVD after adjusting for major sociodemographic, 
lifestyle, and comorbidity risk factors, including physical 
activity, alcohol consumption, and smoking; 3) to stratify 
COPD as a CVD risk factor in different age and gender 
groups; 4) to determine in a case-control study whether 
COPD plays a role as an independent risk for cardiovascular 
morbidity amplifying effect of smoking. We hypothesized 
that the diagnosis of “COPD” increases the risk of having 
CVD, independently of smoking history, age, gender, and 
lifestyle risks known to lead to CVD.
Methods
study setting and sample
Data from the sample adult core of 2002 NHIS15 were 
analyzed. The value of the NHIS data set lies in the design 
of its field instrument which permits the collection of a broad 
range of demographic, socioeconomic, and health behavior 
data along with the prevalence of illness and disability.16 For 
the sample adult core, one adult per family was randomly 
selected to complete a computer-assisted personal interview. 
The NHIS provides final weights accounting for a complex 
sampling design and allowing population-based estimates. 
Though the NHIS collected self-reported data, previous 
studies have confirmed the validity and analysis of this type 
of data.17–20 In this study all subjects 18 years and older were 
included in analyses. Subjects with missing data who did 
not ascertained, refused, or did not know responses were 
excluded from analyses.
CVD status
CVD status was the primary outcome variable of interest. 
Subjects were asked whether a doctor or other health 
professional told them that they had congestive heart failure, 
poor circulation in legs, stroke, coronary heart disease, 
angina (angina pectoris), irregular heartbeats, or heart attack 
(myocardial infarction). Subjects who answered yes to at least 
one of these questions were considered to have CVD. Sub-
jects who answered no to all these conditions were considered 
not to have CVD. Subjects who answered neither “yes” nor 
“no” to these conditions were excluded from analysis. In 
addition to defining “CVD” as above, we defined as outcomes 
each of the individual conditions above.
COPD status
COPD status was ascertained based on the following 
questions: “Have you ever been told by a doctor or other 
health professional that you had emphysema?” and “During 
the past 12 months, have you been told by a doctor or 
other health professional that you had chronic bronchitis?” 
Subjects’ reports of what they were told by physicians may 
not necessarily correspond to the strict medical definition 
of COPD (eg, GOLD criteria). To take this into account 
we analyzed the data using three different definitions of 
“COPD” of increasing strictness: 1) Subjects report having 
“chronic bronchitis” and/or “emphysema”; 2) Same as #1 
and are 40 years old; 3. Same as #2 and report smoking 
more than 100 cigarettes in their lifetime. The last definition 
we felt to be the most likely to correspond to the medical 
definition of COPD and results based on this definition are 
reported below. The two less stringent definitions (1 and 2) 
lead to similar results and conclusions. To characterize the 
study population, the COPD status was further subcatego-
rized as: not having COPD, having chronic bronchitis alone, International Journal of COPD 2009:4 339
COPD as a risk factor of cardiovascular disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
having emphysema alone, or having both chronic bronchitis 
and emphysema.
Risk factors
Sociodemographic variables included age, gender, race/
ethnicity, marital status, education level and family income. 
Race/ethnicity was categorized into: White, Black, Hispanic, 
and other. Subjects with spouse or partner living together 
were considered as married. Education level was divided 
into three groups: had 12 years education, graduated from 
a high school, and had 12 years education. Family income 
was dichotomized as family income less than $20,000 and 
family income of $20,000 or more.
Lifestyle variables included: tobacco use, alcohol con-
sumption and physical activity. Tobacco use was defined 
as current nonsmoker and current smoker. Alcohol use 
was defined as nondrinkers, light, and current drinkers. 
Exercise status was defined as never or ever exercised. 
Comorbid conditions of interest included: hypertension, 
diabetes, hypercholesterolemia, body mass index (BMI) 
status (underweight = BMI  18.5, normal = BMI 18.5–25, 
overweight = BMI  25).
statistical analysis
All statistical analyses were performed using SAS software 
(version 9.1; SAS Institute, Cary, NC, USA). Sampling 
weights were used where applicable to adjust for the 
population-based multistage sampling design.21,22 To incor-
porate the complex sampling design of the NHIS in the 
statistical analysis and to generate data representative of the 
entire US population, SAS procedures SURVEYFREQ and 
SURVEYLOGISTIC were utilized.23 Chi-squared tests were 
employed to compare the prevalence of CVDs in COPD and 
non-COPD population. In addition, the prevalence of each 
individual category of CVDs in COPD, non-COPD subjects 
and non-COPD smokers were also compared.
For cohort analysis, a series of multivariate logistic 
regressions were performed to assess the association 
between any CVD, individual CVD categories and COPD, 
controlling for sociodemographic factors (age, gender, 
race, marital status, education, and family income), health 
behaviors (physical activity, alcohol consumption and current 
tobacco use) and comorbidities (hypertension, diabetes, 
hypercholesterolemia and obesity). The results were reported 
as odds ratios (OR) with corresponding 95% confidence 
intervals (CI). Furthermore, stratified analyses were utilized 
to evaluate the impact of COPD on CVD in different age 
and gender groups. Age was categorized into two adult 
groups aged 40–60 and 60 years. Interactions between 
age group and COPD status, and gender and COPD status 
were also tested.
Smoking is a risk factor common to both CVD and 
COPD. To further explore the possibility that COPD is 
a risk for CVD independent of smoking, we performed a 
matched case-control study drawn from the NHIS 2002 data 
set in which COPD was considered as an exposure factor. 
For this purpose we limited our analysis data set to only 
subjects 40 years old who smoked more than 100 cigarettes 
in their lifetime (smokers). Cases were defined as smokers of 
age 40 years and older who had at least one CVD category 
from above. Overall, 2,975 cases were identified in the 
analysis data set. Each case was matched by age (±1 year), 
gender and race with a control represented by a smoker 
aged 40 years who did not have CVD and who was selected 
randomly from the same analysis data set. The outcome of 
interest was CVD, defined as having at least one of the CVD 
categories above. Regression analysis for matched case-
control studies was used to estimate the association of CVD 
and COPD.24 Conditional logistic regression was employed 
to estimate the hazard ratio (HR) and 95% CI adjusting for 
matched variables and other sociodemographic, lifestyle, 
and comorbid risk factors.
Results
Table 1 shows the characteristics of our study population. 
There were 18,342 subjects who were aged 40 years in our 
cohort and did not have any missing data. Study subjects were 
mostly white (78%), women (53%) with an average age of 
57 years. Most subjects were married (69%) and had higher 
education (51%). About 5% of the subjects had COPD and 
over 28% of the subjects had CVD. Subjects who had CVD 
and COPD were older and had lower family income, tended 
to smoke and do less exercise.
Table 2 lists the prevalence of CVD in COPD, as well as 
various COPD subgroups. Fifty-six percent of COPD patients 
had CVD, while only 26% of the non-COPD subjects had 
CVD, (P  0.0001). Subjects who reported both chronic 
bronchitis and emphysema were more likely to have CVD 
than subjects who reported no COPD, chronic bronchitis 
alone or emphysema alone (P  0.0001).
Table 3 presents the breakdown of individual CVD 
categories. Poor circulation in legs and irregular heartbeats 
were two common conditions in COPD subjects (34% and 
29%, respectively), as well as in non-COPD patients (12% 
and 12%, respectively) and non-COPD smokers (13% and 
13%, respectively). Sixteen percent of COPD patients had International Journal of COPD 2009:4 340
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Table 1 Characteristics of the study population*
Variables 
 
All population 
 
N = 18,342  
% (SE)
COPD  
 
N = 958 
% (SE)
Bronchitis and 
emphysema 
N = 139  
% (SE)
Bronchitis 
alone  
N = 514 
% (SE)
Emphysema 
alone  
N = 305 
% (SE)
COPD and  
CVD  
N = 557  
% (SE)
CVD  
 
N = 5,242   
% (SE)
Age (mean, se) 56.8 
(0.1)
60.3 
(0.4)
61.7 
(0.6)
56.5 
(0.5)
66.3 
(0.5)
62.8 
(0.5)
63.2 
(0.2)
Gender  
  Male 
 
  Female
 
47.0 
(0.4) 
53.0 
(0.4)
 
45.5 
(1.6) 
54.5 
(1.6)
 
46.4 
(1.9) 
53.6 
(1.9)
 
34.1 
(1.8) 
65.9 
(1.8)
 
65.3 
(2.1) 
34.7 
(2.1)
 
44.4 
(1.8) 
55.6 
(1.8)
 
46.4 
(0.8) 
53.6 
(0.8)
Race  
  White  
 
  Black  
 
  hispanic  
 
  Other
 
77.8 
(0.5) 
10.1 
(0.3) 
8.4 
(0.3) 
3.7 
(0.2)
 
85.4 
(1.1) 
8.8 
(0.8) 
4.1 
(0.8) 
1.7 
(0.4)
 
95.6 
(0.1) 
1.5 
(0.04) 
1.4 
(0.04) 
1.5 
(0.04)
 
80.3 
(1.4) 
11.7 
(0.9) 
5.9 
(1.1) 
2.1 
(0.7)
 
89.6 
(1.2) 
7.0 
(0.9) 
2.3 
(0.2) 
1.1 
(0.6)
 
83.0 
(1.4) 
10.7 
(1.0) 
4.8 
(1.1) 
1.5 
(0.4)
 
78.9 
(0.7) 
10.9 
(0.5) 
7.1 
(0.4) 
3.1 
(0.3)
Marital status 
    spouse/partner  
present 
    nonspouse/partner 
present
 
68.6 
(0.4) 
31.4 
(0.4)
 
57.8 
(1.4) 
42.2 
(1.4)
 
52.8 
(2.4) 
47.2 
(2.4)
 
60.0 
(1.6) 
40.0 
(1.6)
 
56.3 
(1.8) 
43.7 
(1.8)
 
54.5 
(1.7) 
45.5 
(1.7)
 
62.5 
(0.8) 
37.5 
(0.8)
Education  
  12 years  
 
  =12 years  
 
  12 years
 
15.8 
(0.3) 
33.5 
(0.4) 
50.7 
(0.5)
 
26.6 
(1.3) 
36.4 
(1.5) 
37.0 
(1.5)
 
42.1 
(1.9) 
29.8 
(1.8) 
28.1 
(1.9)
 
18.1 
(1.7) 
37.5 
(1.9) 
44.4 
(1.9)
 
34.3 
(2.1) 
37.5 
(2.4) 
28.2 
(1.9)
 
32.9 
(1.8) 
35.3 
(1.8) 
31.8 
(1.8)
 
24.2 
(0.7) 
33.8 
(0.8) 
42.0 
(0.8)
Family income 
  Below 20 K 
 
    Above 20 K
 
19.2 
(0.4) 
80.8 
(0.4)
 
34.4 
(1.4) 
65.6 
(1.4)
 
47.5 
(2.1) 
52.5 
(2.1)
 
28.0 
(1.6) 
72.0 
(1.6)
 
39.4 
(2.3) 
60.6 
(2.3)
 
41.6 
(1.8) 
58.4 
(1.8)
 
29.3 
(0.8) 
70.7 
(0.8)
BMI  
    Underweight 
(BMI  18.5)
    normal 
(18.5  BMI  25)
  Overweight (BMI  25)
 
1.4 
(0.1) 
33.2 
(0.4) 
65.4 
(0.5)
 
3.8 
(0.6) 
31.9 
(1.4) 
64.3 
(1.5)
 
4.6 
(0.1) 
33.9 
(2.2) 
61.5 
(2.2)
 
1.9 
(0.4) 
28.0 
(1.6) 
70.1 
(1.7)
 
6.8 
(1.1) 
37.9 
(2.2) 
55.3 
(2.2)
 
3.8 
(0.6) 
30.4 
(1.6) 
65.8 
(1.7)
 
2.0 
(0.18) 
29.6 
(0.8) 
68.4 
(0.8)
Smoking status
  nonsmoker currently
 
  Current smoker
 
80.1 
(0.4) 
19.9 
(0.3)
 
53.7 
(1.7) 
46.3 
(1.7)
44.5 
(2.4) 
55.5 
(2.4)
 
52.9 
(2.0) 
47.1 
(2.0)
 
59.6 
(2.5) 
40.4 
(2.5)
45.5 
(1.7) 
54.5 
(1.7)
 
80.4 
(0.6) 
19.6 
(0.6)
Drinking status
  nondrinker
 
  Light drinker
 
  Drinker
 
22.1 
(0.4) 
50.3 
(0.5) 
27.6 
(0.4)
 
11.7 
(1.0) 
52.6 
(1.6) 
35.7 
(1.6)
 
10.9 
(1.9) 
52.9 
(1.9) 
36.2 
(1.7)
 
12.5 
(1.3) 
57.3 
(1.7) 
30.2 
(1.6)
 
10.8 
(1.4) 
44.0 
(2.5) 
45.2 
(2.6)
 
12.6 
(1.2) 
50.8 
(1.9) 
36.6 
(1.8)
 
24.0 
(0.7) 
47.2 
(0.9) 
28.8 
(0.8)
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coronary heart disease, compared to 6% of non-COPD 
patients and 7% of non-COPD smokers. The difference was 
statistically significant (P  0.0001). In all, subjects with 
COPD were more likely to report any individual CVD cat-
egory than non-COPD patients and non-COPD smokers.
Table 4 shows the association between COPD and 
any CVD and individual CVD categories adjusting for 
sociodemographic factors, health behavior factors and 
comorbidities in multivariate regression model. Subjects 
with COPD had more than twice the risk of CVD than 
subjects without COPD (OR 2.7, 95% CI: 2.3–3.2). Older 
age, lower family income, underweight, smoking, drinking, 
diabetes, hypertension, and high cholesterol were signifi-
cantly associated with increased risk of CVD; while being 
Hispanic, having higher education and exercise were asso-
ciated with significantly reduced the risk of CVD. Further-
more, COPD was significantly associated with all individual 
definitions of CVD categories. Among them, COPD reveals 
the strongest association with congestive heart failure 
(OR 3.9, 95% CI: 2.8–5.5). As well, age, education, income, 
exercise, and comorbidities including diabetes, hypertension 
and high cholesterol indicated consistent relation with each 
individual CVD categories.
Table 5 presents the association of COPD with any CVD 
and individual CVD categories stratified by age and gender. 
The adjusted OR of CVD was three times higher in subjects 
with COPD compared to those without COPD among 
subjects aged from 40 to 60 years, while the OR of CVD 
was twice as high for subjects aged 60 years and older. The 
difference is statistically significant (P = 0.0149). Moreover, 
the ORs for myocardial infarction and irregular heart beat 
were greater in subjects aged 40–60 years than for subjects 
aged 60 years. In gender-related differences, there was no 
significant difference between ORs for CVD or any CVD 
category except for coronary heart disease, which was 
significantly greater in females than in males.
Comparative analysis of health care utilization in COPD 
and CVD subjects was performed to assess affect of concur-
rent COPD and CVD conditions on urgent care utilization, 
hospital stay, doctor office visits, and days missing work. 
About 45% of subjects with both COPD and CVD visited the 
emergency room more than once during the past 12 months 
compared to 38% of COPD patients and 32% of CVD 
patients. Patients who had COPD and CVD tended to have 
more doctor visits during past 12 months than subjects with 
COPD alone and CVD alone. The mean number of days 
missing work at a job for subjects with COPD and CVD was 
22 days, compared to 13 days for subjects with COPD alone 
and 10 days for subjects with CVD alone. Overall, subjects 
who had COPD and CVD had higher health care utilization 
Table 1 (Continued)
Variables 
 
All population 
 
N = 18,342  
% (SE)
COPD  
 
N = 958 
% (SE)
Bronchitis and 
emphysema 
N = 139  
% (SE)
Bronchitis 
alone  
N = 514 
% (SE)
Emphysema 
alone  
N = 305 
% (SE)
COPD and  
CVD  
N = 557  
% (SE)
CVD  
 
N = 5242   
% (SE)
Exercise 
  never 
 
  ever 
 
41.2 
(0.6) 
58.8 
(0.6)
 
57.0 
(1.7) 
43.0 
(1.7)
 
73.3 
(1.4) 
26.7 
(1.4)
 
48.9 
(2.1) 
51.1 
(2.1)
 
63.4 
(2.0) 
36.6 
(2.0)
 
62.4 
(1.8) 
37.6 
(1.8)
 
49.0 
(0.9) 
51.0 
(0.9)
Notes: *COPD definition was based on subject reporting (1) “chronic bronchitis” and/or “emphysema”; (2) age  = 40 years old; (3) smoking more than 100 cigarettes in 
their lifetime.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; se, standard error.
Table 2 CVD prevalence in different COPD categories
Variables 
 
COPD  
 
N = 958  
% (SE)
Non-COPD 
 
N = 17,384  
% (SE)
Bronchitis and 
emphysema 
N = 139 
% (SE)
Bronchitis 
alone 
N = 514  
% (SE)
Emphysema 
alone 
N = 305  
% (SE)
CVD 56.5 25.6 82.3 48.3 58.6
(1.7) (0.4) (3.9) (2.4) (2.9)
non-CVD 43.5 74.4 17.7 51.7 41.4
  (1.7) (0.4) (3.9) (2.4) (2.9)
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; se, standard error.International Journal of COPD 2009:4 342
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than subjects who had COPD alone, and subjects with COPD 
alone had higher health care utilization than subjects with 
CVD alone.
The number of concurrent CVD conditions in COPD 
patients with CVD and patients without COPD who had 
CVD has been assessed. Forty-six percent of the subjects 
with COPD and CVD had just one category of CVD, 
compared to 57% of subjects who smoked, had CVD and 
no COPD. Eighteen percent of the subjects with COPD and 
CVD had more than three CVD categories, compared to 
11% of those CVD, non-COPD smokers. The distribution 
was statistically different between two groups (P  0.0001). 
Thus, patients with COPD (by definition all smokers) were 
more likely to have more categories of CVD than smokers 
without COPD.
The unadjusted OR and adjusted HR of having CVD in 
COPD were calculated in the matched case-control study of 
smokers with and without CVD. The sample was limited to 
the subjects whose age 40 and who smoked 100 cigarettes 
in their lifetime. Cases were those who had either CVD 
category, controls were those who did not have any CVD. 
Cases and controls were matched on age, gender and race. 
There were 2,975 subjects in each group. Seventy-one 
percent of COPD patients had CVD compared to 47% of 
patients without COPD. The unadjusted OR of CVD was 
about threefold higher in patients with COPD than those 
without COPD (OR 2.9, 95% CI: 2.4–3.4). Furthermore, 
COPD was independently and positively associated with 
CVD after adjusting for sociodemographic factors, health 
behavior factors and comorbidities. Patients who had COPD 
had a 2.5 times higher risk of CVD than those without COPD 
(Table 6). Lower family income, drinking and comorbidities 
including diabetes, hypertension and high cholesterol 
were significantly related the increased the risk of CVD. 
Exercise and higher education as well were associated with 
30% and 40% lower risk of CVD respectively compared 
to those who never exercise and had less than 12 years 
education. Current smokers were more likely to have CVD 
than those who did not smoke currently. However this dif-
ference was not statistically significant (P = 0.85).
Discussion
Our results showed that COPD diagnosis remains a strong 
independent predictor of CVD after adjusting for sociode-
mographic, lifestyle, and comorbid risk factors. This study 
included patients from all strata of life and thus it is likely 
to represent the general population. To the best of our 
knowledge, this is the largest cohort of US patients studied in 
which simultaneous adjustment for known sociodemographic 
and behavioral factors and comorbidities associated with 
CVD morbidity was carried out. This is also the first study 
which was able to separate the independent effect of COPD 
on CVD morbidity from effect of smoking by using a case-
control design. Lastly, the impact of COPD as an independent 
risk factor for CVD on the entire US population has not been 
previously determined.
The association between COPD and CVD was evaluated 
in our study using NHIS, which is a representative sample of 
the civilian adult population in the US. First, we measured the 
population-based prevalence of CVD in COPD patients, and 
then evaluated if the diagnosis of COPD is an independent 
risk factor for CVD after adjusting for major sociodemo-
graphic, lifestyle, and comorbid risk factors. Secondly, in our 
case-control study, smokers with CVD (cases) were matched 
with smokers without CVD (controls) by age, race/ethnicity, 
and gender. This allowed separate the cardiovascular effects 
of smoking from the effects of COPD that was considered 
an exposure factor in the analysis of the case-control study. 
Table 3 Prevalence of CVD categories in COPD, non-COPD, and non-COPD smokers
Variables 
 
% in COPD (SE) 
 
N = 958
% in non-COPD (SE) 
 
N = 17,384
P* 
 
% in non-COPD 
smokers (SE) 
N = 8,220
P* 
 
Coronary heart disease 16.1 (1.3) 6.1 (0.2) 0.0001 7.5 (0.3) 0.0001
Angina (Angina pectoris) 11.7 (1.2) 3.9 (0.2) 0.0001 4.8 (0.3) 0.0001
Myocardial infarction 14.8 (1.3) 4.8 (0.2) 0.0001 6.1 (0.3) 0.0001
stroke 8.0 (1.0) 3.6 (0.2) 0.0001 4.1 (0.2) 0.0002
Congestive heart failure 11.4 (1.3) 2.4 (0.1) 0.0001 2.7 (0.2) 0.0001
Poor circulation in legs 33.8 (1.9) 12.1 (0.3) 0.0001 13.5 (0.4) 0.0001
Irregular heart beat 29.0 (1.6) 12.0 (0.3) 0.0001 12.7 (0.4) 0.0001
Note: *Wald Chi-squared test.
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; se, standard error.International Journal of COPD 2009:4 343
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After adjusting for known factors associated with CVD 
morbidity, such as socioeconomic status, marital status, 
education, alcohol consumption, exercise, and concomitant 
conditions including diabetes, hypertension, obesity and 
hypercholesterolemia, COPD diagnosis was still a strong 
predictor of CVD morbidity.
The results of this study are critical given the facts 
known about the pathogenesis of COPD and CVD and the 
increased prevalence of both disease processes within the 
general population. Other studies support the view that 
COPD is an independent risk factor for CVD. Studies by 
Sin and colleagues5,25 showed that the lower the FEV1, the 
higher the risk of CVD. Sin and colleagues defined COPD as 
a reduced FEV1, which is a good indicator but is not specific 
only to COPD. Similar results were reported by Engstrom and 
colleagues who showed that reduced lung function predicted 
fatality in future cardiac events in a population-based study 
from Sweden.26 There was no determination of the revers-
ibility of the airway obstruction in both of these studies. 
Curkendall and colleagues6 showed that the diagnosis of 
COPD increased the morbidity and mortality of CVD using 
a provincial health care database from Canada. This study 
did not fully evaluate the simultaneous impact of sociode-
mographics or lifestyle choices, such as smoking, alcohol 
consumption, physical activity, and how these factors affect 
the association between COPD and CVD.
Our results corroborate the results obtained in previous 
studies evaluating impact of COPD on cardiovascular 
morbidity and mortality. Jousilahti and colleagues reported 
results from a population-based study in eastern Finland 
concluding that chronic bronchitis predicted the risk of 
coronary disease independently from major cardiovascular 
risk factors.27 The analysis of Saskatchewan health databases 
performed by Huiart and colleagues28 showed that cardiovas-
cular morbidity and mortality rates were higher in COPD 
patients than in the general population. Similar results were 
demonstrated by Sidney and colleagues using data from a 
health maintenance organization in northern California.8 
In this study younger patients were shown to have stronger 
relationship of COPD to CVD which corresponds with the 
findings reported in this study. Salisbury and colleagues29 
showed that patients with COPD had poorer health status one 
year after myocardial infarction and greater mortality. This 
corresponds with our results showing that the subjects with 
both COPD and CVD have higher health services utilization 
as compared to the individuals with only one of these two 
conditions. In the Atherosclerosis Risk in Communities 
Study,30 an association between decreased lung function and 
higher prevalence of coronary heart disease was observed. 
This association was stronger in women, which corroborates 
the findings in this study.
Knowing that COPD is an independent risk factor for 
CVD has many repercussions. The importance of recognizing 
and proving the association between COPD and CVD 
supports employing detailed medical work-ups to consider 
treatment for CVD in COPD patients. A concerted effort to 
Table 5 Stratified analysis: Odds ratios of CVD and individual CVD categories by age and gender
Variables  40–60 
N = 11,232
60 
N = 7,110
P†  Male 
N = 7,847
Female 
N = 10,495
P†
Any CVD 3.1**
(2.4, 4.0)
2.2**
(1.7, 2.7)
0.01 2.2**
(1.6, 2.9)
3.2**
(2.5, 4.0)
0.08
Coronary heart disease 2.2**
(1.3, 3.4)
1.8**
(1.4, 2.3)
0.06 1.5*
(1.1, 2.2)
2.5**
(1.8, 3.6)
0.009
Angina (Angina pectoris) 2.3**
(1.4, 3.8)
1.8**
(1.3, 2.5)
0.06 1.9**
(1.4, 2.7)
2.1**
(1.4, 3.2)
0.6
Myocardial infarction 2.8**
(1.8, 4.5)
1.7**
(1.3, 2.4)
0.009 1.8**
(1.2, 2.5)
2.7**
(1.8, 3.9)
0.08
stroke 1.1
(0.6, 2.2)
1.6*
(1.1, 2.3)
0.8 1.6
(0.9, 2.5)
1.4
(0.8, 2.3)
0.9
Congestive heart failure 5.2**
(2.9, 9.1)
3.1**
(2.1, 4.7)
0.1 4.1**
(2.5, 6.6)
3.5**
(2.3, 5.6)
0.6
Poor circulation in legs 2.6**
(1.9, 3.5)
2.2**
(1.7, 2.8)
0.1 1.9**
(1.4, 2.6)
2.9**
(2.2, 3.8)
0.05
Irregular heart beat  2.8** 
(2.1, 3.7)
1.9** 
(1.5, 2.5)
0.03  2.1** 
(1.6, 2.8)
2.6** 
(2.0, 3.3)
0.4 
Notes: †Wald Chi-squared statistics; *P  0.05; **P  0.01.
Abbreviation: CVD, cardiovascular disease.International Journal of COPD 2009:4 346
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evaluate a patient with symptomatic yet undiagnosed COPD 
may be essential to determine a patient’s cardiovascular 
status. Another indication would be to use a preventive 
medicine approach with a COPD patient making lifestyle 
choices clearly protective of CVD in their future. Lastly, 
further investigation of systemic inflammation as a culprit in 
the cascade of ensuing pathology as an underlying primary 
factor in both COPD and CVD is warranted.
The finding that COPD increases the risk for CVD above 
and beyond that of smoking has potentially many important 
implications. It may be, for instance, that patients with COPD 
would do well with therapies that specifically address the 
risk of CVD in addition to those specifically addressing 
the pulmonary issues. Examples of CVD-directed therapy 
which could be evaluated specifically in COPD included beta 
blockers and cholesterol-lowering agents. Such an approach 
is supported by the recent study that showed that the use of 
statins and angiotensin-converting enzyme inhibitors prior 
to admission was associated with decreased mortality in 
subjects hospitalized with COPD exacerbations.31
Smoking, which is prevalent in up to 80% of COPD 
patients, is also a major risk factor for CVD.12 Stavem 
and colleagues found that %FEV1 predicted was a strong 
independent factor of all-cause mortality in current smokers 
whereas it was not associated with mortality among never-
smokers.32 Cigarette smoking and other environmental 
irritants may activate alveolar macrophages, bronchial 
epithelial cells, and other inflammatory cells in adults that 
may be genetically susceptible. They also synthesize elastases 
and metalloproteinases, which promote emphysematous 
changes and airway remodeling. Even in noncurrent smokers 
there was evidence of low-grade inflammation in those 
patients with chronic airflow limitation.33 This suggests that 
long after smoking cessation the inflammation persists and 
can still be a substantial risk factor for CVD.
It has recently been appreciated that COPD, even when 
considered “stable” is a systemic inflammatory disorder. 
Various studies have shown increased levels of inflammatory 
and proinflammatory biomarkers such as C-reactive protein, 
vascular adhesion molecules, fibrinogen levels, reactive 
oxygen species, low CD4/CD8 ratio, cytokines such as 
interleukin-6 (IL-6), IL-8 and tumor necrosis factor-α 
(TNF-α).11,33 A recent study in weight-stable subjects 
with advanced emphysema showed that these patients had 
increased serum TNF receptor levels.34 The presence of 
proinflammatory biomarkers is recognized as an important 
factor in the pathogenesis of artherogenesis.
Several studies suggested the treatment for COPD as 
a possible mechanism linking COPD to CVD.35–37 Beta 
agonists increase cardiovascular morbidity and mortality 
due to direct sympathetic stimulation leading to increased 
heart rate, increase in contractile force, an increase in cardiac 
output, and changes in serum potassium and magnesium 
levels which affect the conduction pathways of the heart.38 
Some studies have failed to show an increased risk of acute 
myocardial infarction and death in patients with COPD 
taking short- and long-acting beta agonists.38 However, in the 
Lung Health Study, Anthonisen and colleagues showed that 
patients receiving ipratropium (Atrovent) had a higher risk 
of arrhythmias. Recent studies provided further evidence of 
the association between inhaled bronchodilators (both beta 
agonists and anticholinergics) and cardiovascular morbidity 
Table 6 Adjusted hazard ratio (hR) of having CVD in COPD 
patients based on the case-control study.    The sample was limited 
to the subjects whose age 40, smoked 100 cigarettes per 
lifetime. Cases were those who had either CVD category, controls 
were those who did not have any CVD.  Cases and controls were 
matched on age, gender, and race
Independent variables HR (95% CI)
COPD 2.5** (2.1, 3.1)
Marital status
  nonspouse/partner present
  spouse/partner present
1
0.9 (0.8, 1.1)
Education
  12 years
  =12 years
  12 years
1
0.6** (0.5, 0.7)
0.7** (0.6, 0.8)
Family income
  Above 20 K
  Below 20 K
1
1.2* (1.0, 1.4)
BMI
  normal (18.5  BMI  25)
  Overweight (BMI  25)
  Underweight (BMI  18.5)
1
1.0 (0.9, 1.2)
1.7* (1.1, 2.8)
Smoking status
  nonsmoker currently
  Current smoker
1
1.0 (0.9, 1.2)
Drinking status
  nondrinker
  Light drinker
  Drinker
1
1.2* (1.0, 1.5)
1.2* (1.0, 1.5)
Exercise
  never
  ever
1
0.7** (0.6, 0.8)
Diabetes 2.1** (1.8, 2.5)
hypertension 2.1** (1.8, 2.4)
high cholesterol 2.3** (2.0, 2.6)
Notes: *P  0.05; **P  0.01.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CVD, cardiovascular disease; hR, hazard ratio.International Journal of COPD 2009:4 347
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and mortality.39–43 The higher risk of CVD among younger 
patients with COPD found in our study may be mediated 
by the use of inhaled bronchodilators which were shown to 
impose a larger relative risk in people with unrecognized 
CVD than in people with known disorders.43 However, the 
mechanism of this association including association between 
the use of inhaled bronchodilators and COPD morbidity and 
mortality was beyond the scope of this study.
The studies cited above certainly are consistent with the 
possibility that the added risk of CVD attributed to COPD 
in smokers is a manifestation of COPD associated inflam-
matory biomarkers. Whether this or other factors account for 
the added risk for CVD in COPD is unknown at this time. 
For example, a recent review of the cohort of the Nurses 
Health Study showed that COPD patients are at increased 
risk of type 2 diabetes,44 in turn an important risk for CVD. 
Another possible factor increasing the risk of CVD in COPD 
is autonomic instability, possibly linked to increased sym-
pathetic drive manifested by decreased respiratory heart 
rate variability.45,46 Newman and colleagues showed that 
COPD was independently associated with increase in coro-
nary artery calcium scores as evidenced by electron beam 
tomography findings.47 Recently, increased arterial stiffness 
was shown to be related to the severity of airflow obstruc-
tion and was suggested to be a factor in the excess risk for 
CVD in COPD.48 Other potential factors in COPD leading to 
increased CVD risk include increased oxygen consumption 
resulting in elevated cardiovascular stress with the need to 
increase peripheral oxygen delivery.49 Finally, COPD patients 
are likely to be more sedentary due to exercise limitation, in 
turn worsening their risk for CVD.50
Because the NHIS survey is based on self-reported 
information, it has inherent limitations.51 Detection of 
COPD is affected by its proper recognition by both the 
study participants and their physicians. The term “chronic 
bronchitis” in the NHIS survey may be misinterpreted 
as recurrent episodes of acute bronchitis. We addressed 
this limitation by introducing more stringent criteria for 
detecting COPD patients including history of smoking and 
aged 40 years and older since most patients with COPD pres-
ent after the fifth decade with positive history of smoking.52 
Overall, the NHIS survey has been administered in US on an 
annual basis since 1957 and was repeatedly demonstrated to 
provide reliable estimates of health-related outcomes in the 
US population.19,20 The data from the NHIS survey has been 
extensively used in population-based epidemiological studies 
related to COPD.53–56 The previous studies have established 
the reliability of self-reported diagnosis.57,58 Absence of data 
on FEV1 may also be interpreted as a limitation. However, 
reduced FEV1 is not specific to COPD and may be manifested 
in other diseases such as congestive heart failure, asthma, 
cystic fibrosis, thoracic kyphosis, multiple sclerosis, and other 
conditions.59–61 At the same time FEV1 in mild COPD (stage 1 
according to the GOLD guidelines)59 can potentially be near 
normal (80%). Postbronchodilator FEV1 and FEV1/FVC 
ratio are required for accurate differential diagnosis and 
severity assessment of COPD,59 however these indicators 
are usually unavailable in administrative databases and 
electronic medical records, which makes it difficult to use 
these indices in population-based studies. In addition, recent 
studies established association between reduced FEV1 with 
nonrespiratory conditions such as stroke, cancer, hip fracture, 
obesity, and diabetes.39,62–64 Based on these considerations 
we felt that not accounting for FEV1 in our analysis did not 
affect the study results. As with any cross-sectional design, 
our study cannot report on causality or temporality.
We believe that the results of this study will increase 
awareness of COPD as an independent risk factor for CVD. 
Better understanding of this association will help us to make 
newer guidelines which will require us to screen for presence 
of COPD in all patients with heart disease and vice versa. 
This should lead to amendment of various guidelines, which 
should include control of COPD, along with control of blood 
pressure, low-density lipoprotein, cholesterol, and other CVD 
risk factors. Considering the role of inflammation in COPD, 
different therapies targeting this aspect may help reduce the 
morbidity and mortality in COPD. This will hopefully help to 
decrease the economic burden of this disease on our society. 
Our results suggest that further studies are warranted in the 
following domains: 1) role and mechanisms of systemic 
inflammation as an underlying factor leading to the higher 
risk of CVD in COPD patients; 2) affect of COPD medica-
tions on CVD morbidity and mortality; and 3) development 
of effective strategies for primary and secondary CVD pre-
vention in patients with COPD.
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